Copyright
        ©The Author(s) 2021.
    
    
        World J Hepatol. Jan 27, 2022; 14(1): 244-259
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.244
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.244
            Table 1 Computed tomography acquisition parameters in study cohort
        
    | CT scanner model | Number of study cases | Detector collimation | Spiral pitch factor | Rotation time (s) | Voltage (kVp) | Tube current-time product at level of liver metastases (mAs) | Noise Index | Reconstruction kernel | Slice thickness/reconstruction interval (mm) | Field of view (cm) | Matrix size (pixels) | 
| GE Lightspeed RT16 | 16 | 16 × 1.25 mm | 1.375:1 | 0.8 (n = 14); 0.9 (n = 1); 1.0 (n = 1) | 120 (n = 14); 140 (n = 2) | 96-300 | 11.5 | SOFT | 1.25/1.25 | 50 | 512 × 512 | 
| GE Optima CT540 | 11 | 16 × 1.25 mm | 1.375:1 (n = 9); 0.938:1 (n = 2) | 0.7 (n = 6); 0.8 (n = 4); 0.9 (n = 1) | 120 | 109.6-277.2 | 11.5 -13 | SOFT | 1.25/1.25 | 50 | 512 × 512 | 
| GE Discovery IQ | 2 | 16 × 1.25 mm | 0.938:1 | 0.8 | 120 | 155.2 and 209.6 | 11-11.5 | SOFT | 1.25/1.25 | 50 | 512 × 512 | 
            Table 2 Characteristics of the patients, overall and by response to first-line chemotherapy
        
    | All | Responders | Non-responders | P valuea | ||||
| n | % | n | % | n | % | ||
| Age at diagnosis (yr)1 | 59 | (52-73) | 60 | (52-74) | 59 | (54-71) | 0.79 | 
| Sex | 1.00 | ||||||
| Female | 11 | (38) | 6 | (40) | 5 | (36) | |
| Male | 18 | (62) | 9 | (60) | 9 | (64) | |
| Position of colorectal Tumor | 0.71 | ||||||
| Colon (incl. rectosigmoid) | 18 | (62) | 10 | (67) | 8 | (57) | |
| Rectum | 11 | (38) | 5 | (33) | 6 | (43) | |
| T-stage of the primary tumor | 1.00 | ||||||
| T3 | 22 | (81) | 11 | (85) | 11 | (79) | |
| T4 | 5 | (19) | 2 | (15) | 3 | (21) | |
| Unknown | 2 | 2 | 0 | ||||
| N-stage of the primary tumor | 0.85 | ||||||
| N0 | 5 | (22) | 2 | (20) | 3 | (23) | |
| N1 | 5 | (22) | 3 | (30) | 2 | (15) | |
| N2 | 13 | (57) | 5 | (50) | 8 | (62) | |
| Unknown | 6 | 5 | 1 | ||||
| Primary CRC grade | 0.60 | ||||||
| Moderate | 25 | (86) | 12 | (80) | 13 | (93) | |
| Poor | 4 | (14) | 3 | (20) | 1 | (7) | |
| M-stage of the primary tumor | 1.00 | ||||||
| M0 | 3 | (10) | 2 | (13) | 1 | (7) | |
| M1 | 26 | (90) | 13 | (87) | 13 | (93) | |
| KRAS mutation status | 1.00 | ||||||
| Wild type | 5 | (42) | 2 | (40) | 3 | (43) | |
| Mutant | 7 | (58) | 3 | (60) | 4 | (57) | |
| Unknown | 17 | 10 | 7 | ||||
| Extent of metastatic disease | 0.71 | ||||||
| Liver only | 18 | (62) | 10 | (67) | 8 | (57) | |
| Liver and extrahepatic | 11 | (38) | 5 | (33) | 6 | (43) | |
| CRLM timing | |||||||
| Synchronous | 26 | (90) | 13 | (87) | 13 | (93) | 1.00 | 
| Metachronous | 3 | (10) | 2 | (13) | 1 | (7) | |
| Number of metastases | 0.05 | ||||||
| ≤ 5 | 10 | (34) | 2 | (13) | 8 | (57) | |
| 6-10 | 7 | (24) | 5 | (33) | 2 | (14) | |
| > 10 | 12 | (41) | 8 | (53) | 4 | (29) | |
| Maximum size of metastases (mm) | 0.49 | ||||||
| < 30 | 8 | (28) | 4 | (27) | 4 | (29) | |
| 30-70 | 15 | (52) | 9 | (60) | 6 | (43) | |
| > 70 | 6 | (21) | 2 | (13) | 4 | (29) | |
| Target liver metastases | |||||||
| Baseline maximum transverse diameter (cm)1 | 2.7 | (2.0-3.3) | 2.9 | (2.6-3.4) | 2.4 | (1.8-3.0) | 0.14 | 
| Baseline lesion volume (cm³)1 | 7.7 | (3.6-12.7) | 8.3 | (6.2-12.2) | 5.2 | (3.1-12.3) | 0.32 | 
| CEA (ng/mL)1 | 107 | (10-171) | 130 | (28-239) | 51 | (11-136) | 0.24 | 
| CA19-9 (IU/mL)1,2 | 127 | (37-377) | 136 | (40-327) | 59 | (21-773) | 0.77 | 
            Table 3 Summary of Response Evaluation Criteria in Solid Tumors response and chemotherapy regimes in response and non-response group
        
    | Response group | Non-response group | |
| RECIST response | ||
| CR | 0 | |
| PR | 15 | |
| SD | 7 | |
| PD | 7 | |
| Chemotherapy regimen | ||
| FOLFOX | 4 | 4 | 
| FOLFIRI | 4 | 3 | 
| FOLFOXIRI | 2 | 0 | 
| CAPE-OX | 2 | 3 | 
| CAPE-IRI | 2 | 3 | 
| Capecitabine | 1 | 1 | 
| Number of chemotherapy cycles between baseline and follow-up scan | ||
| Range in cycles (median) | 3-12 (8) | 3-12 (6) | 
| Time between baseline and follow-up scan | ||
| Range in d (median) | 72-203 (141) | 76-198(111) | 
            Table 4 Radiomic features associated with response to chemotherapy
        
    | Univariable models | Multiple model | |||||
| OR (95%CI) | P value1 | AUC | OR (95%CI) | P value1 | AUC | |
| Minimum histogram gradient intensity | 3.82 (1.26-15.3) | 0.02 | 0.74 | 3.24 (1.05-12.00) | 0.04 | 0.80 | 
| Discretized intensity skewness | 0.33 (0.11-0.86) | 0.02 | 0.73 | |||
| Skewness | 0.33 (0.11-0.86) | 0.02 | 0.73 | |||
| Long run low grey level emphasis | 3.01 (1.16-9.26) | 0.02 | 0.73 | 2.84 (0.98-10.09) | 0.05 | |
| Low grey level count emphasis | 3.01 (1.16-9.26) | 0.02 | 0.73 | |||
| Low grey level run emphasis | 3.01 (1.16-9.26) | 0.02 | 0.73 | |||
| Volume at intensity fraction 10% | 0.33 (0.11-0.86) | 0.02 | 0.73 | |||
| Short run low grey level emphasis | 2.83 (1.08-8.81) | 0.03 | 0.71 | |||
- Citation: Rabe E, Cioni D, Baglietto L, Fornili M, Gabelloni M, Neri E. Can the computed tomography texture analysis of colorectal liver metastases predict the response to first-line cytotoxic chemotherapy? World J Hepatol 2022; 14(1): 244-259
- URL: https://www.wjgnet.com/1948-5182/full/v14/i1/244.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i1.244

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        